Ocuphire Pharma (OCUP) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OCUP vs. PULM, PYXS, IFRX, VTYX, CNTX, RANI, ANRO, AVTX, DERM, and MNPRShould you be buying Ocuphire Pharma stock or one of its competitors? The main competitors of Ocuphire Pharma include Pulmatrix (PULM), Pyxis Oncology (PYXS), InflaRx (IFRX), Ventyx Biosciences (VTYX), Context Therapeutics (CNTX), Rani Therapeutics (RANI), Alto Neuroscience (ANRO), Avalo Therapeutics (AVTX), Journey Medical (DERM), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical preparations" industry. Ocuphire Pharma vs. Pulmatrix Pyxis Oncology InflaRx Ventyx Biosciences Context Therapeutics Rani Therapeutics Alto Neuroscience Avalo Therapeutics Journey Medical Monopar Therapeutics Ocuphire Pharma (NASDAQ:OCUP) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations. Do institutionals and insiders believe in OCUP or PULM? 15.0% of Ocuphire Pharma shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 8.7% of Ocuphire Pharma shares are held by insiders. Comparatively, 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate OCUP or PULM? Ocuphire Pharma currently has a consensus target price of $16.00, suggesting a potential upside of 0.00%. Given Ocuphire Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Ocuphire Pharma is more favorable than Pulmatrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocuphire Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Pulmatrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, OCUP or PULM? Ocuphire Pharma has higher revenue and earnings than Pulmatrix. Pulmatrix is trading at a lower price-to-earnings ratio than Ocuphire Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcuphire Pharma$16.45M0.00-$9.99M-$0.49N/APulmatrix$7.30M3.08-$14.12M-$2.64-2.33 Does the media refer more to OCUP or PULM? In the previous week, Pulmatrix had 5 more articles in the media than Ocuphire Pharma. MarketBeat recorded 6 mentions for Pulmatrix and 1 mentions for Ocuphire Pharma. Pulmatrix's average media sentiment score of 0.32 beat Ocuphire Pharma's score of 0.00 indicating that Pulmatrix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocuphire Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulmatrix 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in OCUP or PULM? Pulmatrix received 159 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. However, 69.81% of users gave Ocuphire Pharma an outperform vote while only 49.00% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformOcuphire PharmaOutperform Votes3769.81% Underperform Votes1630.19% PulmatrixOutperform Votes19649.00% Underperform Votes20451.00% Is OCUP or PULM more profitable? Ocuphire Pharma has a net margin of -85.75% compared to Pulmatrix's net margin of -96.51%. Ocuphire Pharma's return on equity of -30.19% beat Pulmatrix's return on equity.Company Net Margins Return on Equity Return on Assets Ocuphire Pharma-85.75% -30.19% -27.55% Pulmatrix -96.51%-45.97%-30.72% Which has more risk and volatility, OCUP or PULM? Ocuphire Pharma has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. SummaryOcuphire Pharma beats Pulmatrix on 13 of the 18 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Ocuphire Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUP vs. The Competition Export to ExcelMetricOcuphire PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.33M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-2.394.9791.2813.60Price / SalesN/A371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / BookN/A10.306.906.33Net Income-$9.99M$153.61M$118.83M$225.93M Ocuphire Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCUPOcuphire Pharma0.922 of 5 starsN/A$16.00+∞N/A$30.33M$16.45M-2.3914High Trading VolumePULMPulmatrix0.26 of 5 stars$6.15+9.4%N/A+210.5%$22.45M$7.30M-2.2820Analyst ForecastGap UpPYXSPyxis Oncology1.0178 of 5 stars$2.04-46.6%$10.00+390.2%+165.3%$121.32MN/A-1.9660Analyst ForecastNews CoverageGap DownHigh Trading VolumeIFRXInflaRx3.0863 of 5 stars$2.03-0.5%$8.00+294.1%+34.2%$119.53M$70,000.000.0060Gap UpVTYXVentyx Biosciences2.4892 of 5 stars$1.68-2.6%$10.00+497.0%-27.1%$118.44MN/A-0.7373CNTXContext Therapeutics2.0835 of 5 stars$1.53-6.1%$6.25+308.5%+81.1%$114.75MN/A-1.797Gap DownRANIRani Therapeutics3.1632 of 5 stars$2.04-0.5%$11.71+474.2%+2.5%$108.96M$2.72M0.00110Analyst ForecastANROAlto Neuroscience3.8056 of 5 stars$3.96-7.3%$20.00+405.1%N/A$106.80M$210,000.000.00N/AAnalyst RevisionAVTXAvalo Therapeutics2.3577 of 5 stars$10.26-5.9%N/A-47.4%$106.60M$1.92M0.0040Positive NewsDERMJourney Medical3.2183 of 5 stars$5.12-2.1%$9.38+83.1%N/A$106.14M$79.18M-5.5690Analyst RevisionNews CoverageMNPRMonopar Therapeutics3.5896 of 5 stars$19.70+3.7%$27.33+38.7%+1,213.5%$104.02MN/A0.0010 Related Companies and Tools Related Companies Pulmatrix Alternatives Pyxis Oncology Alternatives InflaRx Alternatives Ventyx Biosciences Alternatives Context Therapeutics Alternatives Rani Therapeutics Alternatives Alto Neuroscience Alternatives Avalo Therapeutics Alternatives Journey Medical Alternatives Monopar Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCUP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocuphire Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
